FAG
AKRO

Fortitude Advisory Group’s Akero Therapeutics AKRO Stock Holding History

Fortitude Advisory Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-71
Closed -$1K – 236
2022
Q1 		$1K Hold
71
– – ﹤0.01% 1419
2021
Q4 		$2K Buy
+71
New +$1.57K ﹤0.01% 1358

Other funds holding AKRO

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fortitude Advisory Group's AKRO Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Akero Therapeutics (AKRO) in Q2 2022, closing a stake of 71 shares — an estimated $1K sold.

Fortitude Advisory Group first reported a position in AKRO in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 113 funds tracked by Wall St. Rank hold AKRO as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Akero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 71 Akero Therapeutics shares in Q2 2022, an estimated $1K.
  • Fortitude Advisory Group first reported a position in Akero Therapeutics in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Akero Therapeutics position peaked at $2K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.